Johnson & Johnson (NYSE:JNJ) Sets New 1-Year High – Here’s What Happened

Posted by George Bondi on Jul 28th, 2026

Johnson & Johnson (NYSE:JNJ – Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $274.90 and last traded at $272.4110, with a volume of 1038902 shares trading hands. The stock had previously closed at $265.95.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson agreed to pay up to $5.5 billion to resolve roughly 76,000 remaining claims alleging that its talc products caused ovarian cancer. The agreement requires participation by at least 95% of claimants, but investors viewed the proposal as a potentially important step toward containing litigation risk after more than a decade of legal battles. Johnson & Johnson settling talc baby powder lawsuits for $5.5 billion
Positive Sentiment: Morgan Stanley maintained its Buy rating and $294 price target, indicating that settlement progress may improve JNJ’s risk profile and leave room for further appreciation from current levels. Johnson & Johnson: Talc Settlement Progress Supports Buy Rating
Positive Sentiment: Johnson & Johnson’s second-quarter results exceeded expectations, with revenue rising 6.6% to $25.31 billion and adjusted earnings reaching $2.90 per share. The company also raised its full-year outlook to $11.60–$11.75 in adjusted EPS, supporting confidence in operating momentum. Johnson & Johnson Raised Its Outlook

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Guggenheim reaffirmed a “buy” rating and issued a $270.00 target price on shares of Johnson & Johnson in a report on Friday, July 17th. Johnson Rice raised Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 price target on the stock in a research note on Thursday, July 16th. Sanford C. Bernstein upped their price target on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a report on Wednesday, April 15th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, TD Cowen boosted their target price on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $265.30.

Check Out Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Trading Up 2.5%

The company has a market cap of $656.99 billion, a price-to-earnings ratio of 31.54, a PEG ratio of 2.50 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The business’s 50-day simple moving average is $243.46 and its 200-day simple moving average is $236.98.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period in the prior year, the business earned $2.77 earnings per share. The company’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts predict that Johnson & Johnson will post 11.68 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.11%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. Greenberg Financial Group acquired a new position in Johnson & Johnson in the fourth quarter valued at $954,000. World Investment Advisors increased its stake in Johnson & Johnson by 19.6% during the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after acquiring an additional 26,450 shares during the last quarter. Benchmark Financial LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $554,000. Principal Financial Group Inc. lifted its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock valued at $705,736,000 after purchasing an additional 28,370 shares in the last quarter. Finally, Robinhood Asset Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $11,853,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.